Idexx Laboratories Inc (IDXX) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Idexx Laboratories reported revenue of $4.30B, up 10.4% from $3.90B the year before. Net income was $1.06B (a 24.6% net margin), or $13.08 per diluted share. Gross margin was 61.8% and operating margin was 31.6%. Operating activities generated $1.18B of cash, leaving $1.06B of free cash flow. At fiscal year end, Idexx Laboratories held $3.35B in total assets against $1.75B in total liabilities, including $180.1M of cash and equivalents.
Open the full interactive Idexx Laboratories financials → Quarterly statements, key ratios, valuation history and price charts.
Idexx Laboratories Key Stats
| Share Price | $520.31 |
|---|---|
| Market Cap | $41.27B |
| P/E Ratio | 39.8 |
| Revenue YoY Growth | +10.4% |
| 52-Week Range | $504.70 – $766.68 |
| Shares Outstanding | 79.0 million (basic, 2026 Q2) |
Idexx Laboratories Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.71B | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Cost of Goods Sold | — | — | — | — | $1.52B | $1.64B |
| Gross Profit | $1.57B | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Operating Income | $694.5M | $932.0M | $898.8M | $1.10B | $1.13B | $1.36B |
| Pre-Tax Income | $662.0M | $902.7M | $860.0M | $1.06B | $1.11B | $1.32B |
| Income Tax | $79.9M | $157.8M | $180.9M | $216.1M | $222.0M | $264.7M |
| Net Income | $581.8M | $744.8M | $679.1M | $845.0M | $887.9M | $1.06B |
| Diluted EPS | $6.71 | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
Idexx Laboratories Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.11B | $1.09B | $1.14B | $1.22B |
| Net Income | $274.6M | $248.2M | $278.4M | $338.4M |
| Diluted EPS | $3.40 | $3.06 | $3.47 | $4.27 |
Idexx Laboratories Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $383.9M | $144.5M | $112.5M | $453.9M | $288.3M | $180.1M |
| Current Assets | $1.06B | $955.7M | $1.10B | $1.50B | $1.40B | $1.41B |
| Total Assets | $2.29B | $2.44B | $2.75B | $3.26B | $3.29B | $3.35B |
| Current Liabilities | $582.8M | $763.6M | $1.24B | $951.5M | $1.07B | $1.15B |
| Total Long-Term Debt | $908.5M | $850.2M | $769.4M | $697.9M | $617.6M | $449.8M |
| Total Liabilities | $1.66B | $1.75B | $2.14B | $1.78B | $1.70B | $1.75B |
| Shareholders' Equity | $632.1M | $690.0M | $608.7M | $1.48B | $1.60B | $1.61B |
Idexx Laboratories Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $648.1M | $755.5M | $543.0M | $906.5M | $929.0M | $1.18B |
| Cash From Investing | -$109.4M | -$293.0M | -$195.3M | -$125.3M | -$207.1M | -$136.2M |
| Cash From Financing | -$248.4M | -$697.4M | -$370.9M | -$442.0M | -$878.1M | -$1.16B |
| Free Cash Flow | $541.1M | $636.0M | $394.1M | $772.9M | $808.1M | $1.06B |
Figures from Idexx Laboratories' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Idexx Laboratories financials page for every line item.
Idexx Laboratories Company Profile
| Ticker | IDXX |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Westbrook, Maine |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000874716 |
Frequently Asked Questions
What was Idexx Laboratories' revenue in fiscal 2025?
Idexx Laboratories (IDXX) reported revenue of $4.30B for fiscal 2025.
What is Idexx Laboratories' annual revenue history?
Idexx Laboratories' annual revenue by fiscal year: 2020: $2.71B; 2021: $3.22B; 2022: $3.37B; 2023: $3.66B; 2024: $3.90B; 2025: $4.30B.
What was Idexx Laboratories' net income in fiscal 2025?
Idexx Laboratories reported net income of $1.06B for fiscal 2025.
What was Idexx Laboratories' earnings per share (EPS) in fiscal 2025?
Idexx Laboratories' diluted EPS was $13.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Idexx Laboratories generate in fiscal 2025?
Idexx Laboratories generated $1.06B of free cash flow in fiscal 2025.
What was Idexx Laboratories' revenue last quarter?
In its most recent reported quarter (2026 Q2), Idexx Laboratories reported revenue of $1.22B.
How much debt does Idexx Laboratories have?
Idexx Laboratories reported $449.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Idexx Laboratories are outstanding?
Idexx Laboratories reported a weighted average of 79.0 million basic shares outstanding in 2026 Q2.
What is Idexx Laboratories' market cap?
Based on its latest closing price, Idexx Laboratories (IDXX) has a market capitalization of about $41.27B.
When does Idexx Laboratories' fiscal year end?
Idexx Laboratories' fiscal year end, as registered with the SEC, is December 31.
Where is Idexx Laboratories headquartered?
Idexx Laboratories lists its business address in Westbrook, Maine in its SEC filings.
Idexx Laboratories Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →